<doc>
  <docmeta id="113hr928ih">
    <bill congress="113" type="hr" number="928" version="ih"/>
    <revision size="22748" annotations="0" id="8" commit-time="2013-03-29T18:12:10+00:00" committer="favila" doc="113hr928ih/8.xml" status="complete">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H8FC21660CCED4E72AFBBA42F90B13C7F" public-private="public">
	<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 928</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130228">February 28, 2013</action-date>
			<action-desc>
        <sponsor name-id="S001145">Ms. Schakowsky</sponsor> (for
			 herself, <cosponsor name-id="F000030">Mr. Farr</cosponsor>,
			 <cosponsor name-id="L000551">Ms. Lee of California</cosponsor>,
			 <cosponsor name-id="M000725">Mr. George Miller of California</cosponsor>, and
			 <cosponsor name-id="P000597">Ms. Pingree of Maine</cosponsor>) introduced the
			 following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in
			 addition to the Committee on <committee-name committee-id="HWM00">Ways and
			 Means</committee-name>, for a period to be subsequently determined by the
			 Speaker, in each case for consideration of such provisions as fall within the
			 jurisdiction of the committee concerned</action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend title XVIII of the Social Security Act to
		  deliver a meaningful benefit and lower prescription drug prices under the
		  Medicare Program.</official-title>
	</form>
	<legis-body id="H4794E6AD368543F89F361210A17E5CF4" style="OLC">
		<section display-inline="no-display-inline" id="H9A50376F04A745B1BBD451758ADFD99D" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the
			 <quote>
          <short-title>Medicare Prescription Drug Savings and
			 Choice Act of 2013</short-title>
        </quote>.</text>
		</section>
    <section id="H56A74351F92749F5B6C13719EAE830B0">
      <enum>2.</enum>
      <header>Establishment of
			 Medicare operated prescription drug plan option</header>
			<subsection id="H56A3503C6D044578BF857B302A4285F1">
        <enum>(a)</enum>
        <header>In
			 general</header>
        <text>
          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/t:XVIII/pt:D/spt:2">Subpart 2 of part D of title XVIII of the Social Security
			 Act</cato:entity-ref> is amended by inserting after <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Social Security Act/s:1860D–11">section 1860D–11</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/1395w–111">42 U.S.C. 1395w–111</cato:entity-ref>)</cato:entity> the
			 following new section:</text>
				<quoted-block act-name="Social Security Act" id="HC4D0B43320CD4CEC829341B9DCD8042D" style="traditional">
					<section id="H772A210AF7BC4876B1659D837BD7A343">
            <enum>1860D–11A.</enum>
            <header>Medicare operated prescription drug plan
		  option</header>
            <subsection commented="no" display-inline="yes-display-inline" id="HEE9B43FCFC6C430F819649AF2D3C05B7">
              <enum>(a)</enum>
              <header>In
				general</header>
              <text display-inline="yes-display-inline">Notwithstanding any
				other provision of this part, for each year (beginning with 2012), in addition
				to any plans offered under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D–11">section 1860D–11</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall offer one or
				more Medicare operated prescription drug plans (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D-11A/ss:c" proposed="true">subsection (c)</cato:entity-ref>)
				with a service area that consists of the entire United States and shall enter
				into negotiations in accordance with subsection (b) with pharmaceutical
				manufacturers to reduce the purchase cost of covered part D drugs for eligible
				part D individuals who enroll in such a plan.</text>
						</subsection>
            <subsection id="HE1B68656E90C46E1AD5BC814D8B35077">
              <enum>(b)</enum>
              <header>Negotiations</header>
              <text display-inline="yes-display-inline">Notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D–11/ss:i">section 1860D–11(i)</cato:entity-ref>, for
				purposes of offering a Medicare operated prescription drug plan under this
				section, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall negotiate with pharmaceutical manufacturers with
				respect to the purchase price of covered part D drugs in a Medicare operated
				prescription drug plan and shall encourage the use of more affordable
				therapeutic equivalents to the extent such practices do not override medical
				necessity as determined by the prescribing physician. To the extent practicable
				and consistent with the previous sentence, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall implement
				strategies similar to those used by other Federal purchasers of prescription
				drugs, and other strategies, including the use of a formulary and formulary
				incentives in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D-11A/ss:e" proposed="true">subsection (e)</cato:entity-ref>, to reduce the purchase cost of covered part D
				drugs.</text>
						</subsection>
            <subsection id="H4B84CA5A79B841558B0ED48DA7845D0D">
              <enum>(c)</enum>
              <header>Medicare
				operated prescription drug plan defined</header>
              <text>For purposes of this
				part, the term <term>Medicare operated prescription drug plan</term> means a
				prescription drug plan that offers qualified prescription drug coverage and
				access to negotiated prices described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D–2/ss:a/p:1/sp:A">section 1860D–2(a)(1)(A)</cato:entity-ref>. Such a plan
				may offer supplemental prescription drug coverage in the same manner as other
				qualified prescription drug coverage offered by other prescription drug
				plans.</text>
						</subsection>
            <subsection id="HB44A31F7D5D9435283230EF90EABC785">
              <enum>(d)</enum>
              <header>Monthly
				beneficiary premium</header>
							<paragraph id="H4F4EF94FE8F0453590957D356D7DEF7E">
                <enum>(1)</enum>
                <header>Qualified
				prescription drug coverage</header>
                <text>The monthly beneficiary premium for
				qualified prescription drug coverage and access to negotiated prices described
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D–2/ss:a/p:1/sp:A">section 1860D–2(a)(1)(A)</cato:entity-ref> to be charged under a Medicare operated
				prescription drug plan shall be uniform nationally. Such premium for months in
				2014 and each succeeding year shall be based on the average monthly per capita
				actuarial cost of offering the Medicare operated prescription drug plan for the
				year involved, including administrative expenses.</text>
							</paragraph>
              <paragraph id="HC2A96641380F49E2A817D0150C4090E2">
                <enum>(2)</enum>
                <header>Supplemental
				prescription drug coverage</header>
                <text>Insofar as a Medicare operated
				prescription drug plan offers supplemental prescription drug coverage, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may adjust the amount of the premium charged under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D-11A/ss:d/p:1" proposed="true">paragraph
				(1)</cato:entity-ref>.</text>
							</paragraph>
            </subsection>
            <subsection id="HBA8EDE4C9E5D4001A4226DA1C987766F">
              <enum>(e)</enum>
              <header>Use of a
				formulary and formulary incentives</header>
							<paragraph id="HB064DB7ACC294FBEB3BC425AF4EE071A">
                <enum>(1)</enum>
                <header>In
				general</header>
                <text display-inline="yes-display-inline">With respect to the
				operation of a Medicare operated prescription drug plan, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				establish and apply a formulary (and may include formulary incentives described
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D-11A/ss:e/p:2/sp:C/cl:ii" proposed="true">paragraph (2)(C)(ii)</cato:entity-ref>) in accordance with this subsection in order to—</text>
								<subparagraph id="H4A77867917B546CF9C54AE8D32336136">
                  <enum>(A)</enum>
                  <text>increase patient
				safety;</text>
								</subparagraph>
                <subparagraph id="H86C9611005E24F5DA3BA297963831F05">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">increase appropriate use and reduce
				inappropriate use of drugs; and</text>
								</subparagraph>
                <subparagraph id="HE148987A34C94CE5A1BD76AF1F312CFC">
                  <enum>(C)</enum>
                  <text>reward
				value.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H11D76EF2DCAA440E9BAE3E35E27E864E">
                <enum>(2)</enum>
                <header>Development of
				initial formulary</header>
								<subparagraph id="H19F7376C78CF40BA9D463F87FB901E10">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text display-inline="yes-display-inline">In selecting covered
				part D drugs for inclusion in a formulary, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall consider
				clinical benefit and price.</text>
								</subparagraph>
                <subparagraph id="H4221D0EC6B6647E6A6B1836618C9EE93">
                  <enum>(B)</enum>
                  <header>Role of
				AHRQ</header>
                  <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7528">Director of the
				Agency for Healthcare Research and Quality</cato:entity-ref> shall be responsible for assessing
				the clinical benefit of covered part D drugs and making recommendations to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> regarding which drugs should be included in the formulary. In
				conducting such assessments and making such recommendations, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7528">Director</cato:entity-ref>
				shall—</text>
									<clause id="H6976F29F2D3E4B5CAD9FBA7F75B1DA10">
                    <enum>(i)</enum>
                    <text>consider safety
				concerns including those identified by the Federal <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug
				Administration</cato:entity-ref>;</text>
									</clause>
                  <clause id="H86FB72A4B60C47D692B1C4D458A475B9">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">use available data and evaluations, with
				priority given to randomized controlled trials, to examine clinical
				effectiveness, comparative effectiveness, safety, and enhanced compliance with
				a drug regimen;</text>
									</clause>
                  <clause id="H538C6215DE244CFFBE3587C132195F00">
                    <enum>(iii)</enum>
                    <text>use the same
				classes of drugs developed by United States Pharmacopeia for this part;</text>
									</clause>
                  <clause id="H6460E9A88B094708B9395C80A330D09F">
                    <enum>(iv)</enum>
                    <text>consider
				evaluations made by—</text>
										<subclause id="HEBFB0D1C0BAE4702A9B2261EC3F802E1">
                      <enum>(I)</enum>
                      <text>the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7528">Director</cato:entity-ref> under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1013">section 1013 of Medicare Prescription Drug, Improvement, and Modernization Act
				of 2003</cato:entity-ref>;</text>
										</subclause>
                    <subclause id="HB2DC7B7470524BCC98A7517C8010EEC5">
                      <enum>(II)</enum>
                      <text>other Federal
				entities, such as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="3600">Secretary of Veterans Affairs</cato:entity-ref>; and</text>
										</subclause>
                    <subclause id="H9FF1053C604942D780703F9CE67AF54D">
                      <enum>(III)</enum>
                      <text>other private
				and public entities, such as the Drug Effectiveness Review Project and Medicaid
				programs; and</text>
										</subclause>
                  </clause>
                  <clause id="H82BFE11C14384EE3980D9F577072BA75">
                    <enum>(v)</enum>
                    <text>recommend to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>—</text>
										<subclause id="H3C21577C06EC44B4B736C36BB0ECB55A">
                      <enum>(I)</enum>
                      <text display-inline="yes-display-inline">those drugs in a class that provide a
				greater clinical benefit, including fewer safety concerns or less risk of
				side-effects, than another drug in the same class that should be included in
				the formulary;</text>
										</subclause>
                    <subclause id="HB3781D2D8908431198D3FD0F3A673759">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">those drugs in a class that provide less
				clinical benefit, including greater safety concerns or a greater risk of
				side-effects, than another drug in the same class that should be excluded from
				the formulary; and</text>
										</subclause>
                    <subclause id="H28FAAB2748984CB4A0E0C15C352EA815">
                      <enum>(III)</enum>
                      <text>drugs in a class
				with same or similar clinical benefit for which it would be appropriate for the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> to competitively bid (or negotiate) for placement on the
				formulary.</text>
										</subclause>
                  </clause>
                </subparagraph>
                <subparagraph id="HFD62FDC643F942D781C1A19955C0F9C6">
                  <enum>(C)</enum>
                  <header>Consideration of
				AHRQ recommendations</header>
									<clause id="H36129663BA6C49F897BE408FDE8D5459">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, after
				taking into consideration the recommendations under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D-11A/ss:e/p:2/sp:B/cl:v" proposed="true">subparagraph (B)(v)</cato:entity-ref>, shall
				establish a formulary, and formulary incentives, to encourage use of covered
				part D drugs that—</text>
										<subclause id="H07F3D278B56C43339C7E42D0264B442B">
                      <enum>(I)</enum>
                      <text display-inline="yes-display-inline">have a lower cost and provide a greater
				clinical benefit than other drugs;</text>
										</subclause>
                    <subclause id="H2E53528F0E7442BE8141CCD0C054002A">
                      <enum>(II)</enum>
                      <text display-inline="yes-display-inline">have a lower cost than other drugs with
				same or similar clinical benefit; and</text>
										</subclause>
                    <subclause id="H0C5298EB2C054765A176E9DFAA2B7F5E">
                      <enum>(III)</enum>
                      <text display-inline="yes-display-inline">drugs that have the same cost but provide
				greater clinical benefit than other drugs.</text>
										</subclause>
                  </clause>
                  <clause id="H145965C15C3E48048E91CBBE68CA1E03">
                    <enum>(ii)</enum>
                    <header>Formulary
				incentives</header>
                    <text display-inline="yes-display-inline">The formulary
				incentives under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D-11A/ss:e/p:2/sp:C/cl:i" proposed="true">clause (i)</cato:entity-ref> may be in the form of one or more of the
				following:</text>
										<subclause id="HE812D696028244C7AE1201E77B2F9159">
                      <enum>(I)</enum>
                      <text display-inline="yes-display-inline">Tiered copayments.</text>
										</subclause>
                    <subclause id="HAF339E88185F4B68885ED79E31643EAB">
                      <enum>(II)</enum>
                      <text>Reference
				pricing.</text>
										</subclause>
                    <subclause id="H2750E3A099A8407EB5143ACDAB01971E">
                      <enum>(III)</enum>
                      <text>Prior
				authorization.</text>
										</subclause>
                    <subclause id="HBF928DA0407F44A0927F9D8ADE9E8695">
                      <enum>(IV)</enum>
                      <text>Step
				therapy.</text>
										</subclause>
                    <subclause id="HE04B3FFE5FE94AD98DC1B7737D3BD463">
                      <enum>(V)</enum>
                      <text>Medication therapy
				management.</text>
										</subclause>
                    <subclause id="H6A773E08E528424C99258C0F9A8389D5">
                      <enum>(VI)</enum>
                      <text display-inline="yes-display-inline">Generic drug substitution.</text>
										</subclause>
                  </clause>
                  <clause id="H0724D3C331A94A269623D37AD2E121ED">
                    <enum>(iii)</enum>
                    <header>Flexibility</header>
                    <text display-inline="yes-display-inline">In applying such formulary incentives the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may decide not to impose any cost-sharing for a covered part D drug
				for which—</text>
										<subclause id="HD565BB4B1FCD4DDA8B4D4868D6C11217">
                      <enum>(I)</enum>
                      <text>the elimination of
				cost sharing would be expected to increase compliance with a drug regimen;
				and</text>
										</subclause>
                    <subclause id="H04B56F6AC7524BBDAAE188A463951C59">
                      <enum>(II)</enum>
                      <text>compliance would
				be expected to produce savings under part A or B or both.</text>
										</subclause>
                  </clause>
                </subparagraph>
              </paragraph>
              <paragraph id="H0D309B78FE1C4C38996216341905ADAB">
                <enum>(3)</enum>
                <header>Limitations on
				formulary</header>
                <text>In any formulary established under this subsection, the
				formulary may not be changed during a year, except—</text>
								<subparagraph id="HEA14EBDD2EAF49E097C5E61B21B22BD7">
                  <enum>(A)</enum>
                  <text>to add a generic
				version of a covered part D drug that entered the market;</text>
								</subparagraph>
                <subparagraph id="HFEF98D5E39BB4AD08C38DBBE4B189F56">
                  <enum>(B)</enum>
                  <text>to remove such a
				drug for which a safety problem is found; and</text>
								</subparagraph>
                <subparagraph id="H8BE98E81217543CF88594304C70AA470">
                  <enum>(C)</enum>
                  <text display-inline="yes-display-inline">to add a drug that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> identifies
				as a drug which treats a condition for which there has not previously been a
				treatment option or for which a clear and significant benefit has been
				demonstrated over other covered part D drugs.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HED4C6BC4590B42369815ACFDCC4BD6E2">
                <enum>(4)</enum>
                <header>Adding drugs to
				the initial formulary</header>
								<subparagraph id="H675F69A2E7D9498B8CAB522BF770B336">
                  <enum>(A)</enum>
                  <header>Use of advisory
				committee</header>
                  <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				establish and appoint an advisory committee (in this paragraph referred to as
				the <term>advisory committee</term>)—</text>
									<clause id="H62F35AC608D84614A39220BCEE2A438F">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">to review petitions from drug
				manufacturers, health care provider organizations, patient groups, and other
				entities for inclusion of a drug in, or other changes to, such formulary;
				and</text>
									</clause>
                  <clause id="HC0A662B7A7D046A3A73846D6E5E2F2CF">
                    <enum>(ii)</enum>
                    <text>to recommend any
				changes to the formulary established under this subsection.</text>
									</clause>
                </subparagraph>
                <subparagraph id="HA41F40B87BB94A1DA538F9D561596844">
                  <enum>(B)</enum>
                  <header>Composition</header>
                  <text display-inline="yes-display-inline">The advisory committee shall be composed of
				9 members and shall include representatives of physicians, pharmacists, and
				consumers and others with expertise in evaluating prescription drugs. The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall select members based on their knowledge of pharmaceuticals and
				the Medicare population. Members shall be deemed to be special Government
				employees for purposes of applying the conflict of interest provisions under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/18/208">section 208 of title 18, United States Code</cato:entity-ref>, and no waiver of such provisions
				for such a member shall be permitted.</text>
								</subparagraph>
                <subparagraph id="H44B04210B013448AA34C3165B9950949">
                  <enum>(C)</enum>
                  <header>Consultation</header>
                  <text>The
				advisory committee shall consult, as necessary, with physicians who are
				specialists in treating the disease for which a drug is being
				considered.</text>
								</subparagraph>
                <subparagraph id="HFC09F2AB32B642DAAEA156C3FA1A360D">
                  <enum>(D)</enum>
                  <header>Request for
				studies</header>
                  <text display-inline="yes-display-inline">The advisory
				committee may request the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7528">Agency for Healthcare Research and Quality</cato:entity-ref> or an
				academic or research institution to study and make a report on a petition
				described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D-11A/ss:e/p:4/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref> in order to assess—</text>
									<clause id="HEB048B52FABE41C2854DEAFCE5683774">
                    <enum>(i)</enum>
                    <text>clinical
				effectiveness;</text>
									</clause>
                  <clause id="HA766A5D1D66A41CA9B0E4B433E62251D">
                    <enum>(ii)</enum>
                    <text>comparative
				effectiveness;</text>
									</clause>
                  <clause id="HA77381C41DB2418A87625B89121C3624">
                    <enum>(iii)</enum>
                    <text>safety;
				and</text>
									</clause>
                  <clause id="HC25BF25184FA4DB2AF7962863B383A4E">
                    <enum>(iv)</enum>
                    <text>enhanced
				compliance with a drug regimen.</text>
									</clause>
                </subparagraph>
                <subparagraph id="HF3081983A8174BF5AF56CA4334F7B549">
                  <enum>(E)</enum>
                  <header>Recommendations</header>
                  <text>The
				advisory committee shall make recommendations to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				regarding—</text>
									<clause id="HC0729CDE8F1949C38C43702D1B73B61B">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">whether a covered part D drug is found to
				provide a greater clinical benefit, including fewer safety concerns or less
				risk of side-effects, than another drug in the same class that is currently
				included in the formulary and should be included in the formulary;</text>
									</clause>
                  <clause id="H7B77258313304BB09A964FE0BBFAD5B1">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">whether a covered part D drug is found to
				provide less clinical benefit, including greater safety concerns or a greater
				risk of side-effects, than another drug in the same class that is currently
				included in the formulary and should not be included in the formulary;
				and</text>
									</clause>
                  <clause id="H31DD557599AB42598CF4E08493EB1136">
                    <enum>(iii)</enum>
                    <text>whether a
				covered part D drug has the same or similar clinical benefit to a drug in the
				same class that is currently included in the formulary and whether the drug
				should be included in the formulary.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H4BB676D3640849A8925C0B01B80DC219">
                  <enum>(F)</enum>
                  <header>Limitations on
				review of manufacturer petitions</header>
                  <text display-inline="yes-display-inline">The advisory committee shall not review a
				petition of a drug manufacturer under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D-11A/ss:e/p:4/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref> with respect to a
				covered part D drug unless the petition is accompanied by the following:</text>
									<clause id="HD3EB95A0F6DB45C1B486EAF18F55067D">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">Raw data from clinical trials on the safety
				and effectiveness of the drug.</text>
									</clause>
                  <clause id="HE84860BAD2A44F6494D411C13AC84C36">
                    <enum>(ii)</enum>
                    <text>Any data from
				clinical trials conducted using active controls on the drug or drugs that are
				the current standard of care.</text>
									</clause>
                  <clause id="H6DEAC541BB504B10BA34672433E53330">
                    <enum>(iii)</enum>
                    <text>Any available
				data on comparative effectiveness of the drug.</text>
									</clause>
                  <clause id="H77201BE84A214FE6B46D4799E954C499">
                    <enum>(iv)</enum>
                    <text>Any other
				information the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> requires for the advisory committee to complete its
				review.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H3C5240F618B64C5CA0CACFFA5952103C">
                  <enum>(G)</enum>
                  <header>Response to
				recommendations</header>
                  <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall review the recommendations of the advisory committee and if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				accepts such recommendations the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall modify the formulary
				established under this subsection accordingly. Nothing in this section shall
				preclude the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> from adding to the formulary a drug for which the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7528">Director of the Agency for Healthcare Research and Quality</cato:entity-ref> or the advisory
				committee has not made a recommendation.</text>
								</subparagraph>
                <subparagraph id="HD09640C9BB5B4B6497A83CDB8D2EBC1D">
                  <enum>(H)</enum>
                  <header>Notice of
				changes</header>
                  <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				provide timely notice to beneficiaries and health professionals about changes
				to the formulary or formulary incentives.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="HCF7C7EF41F3440ABAB2FCDC5C5AF1A42">
              <enum>(f)</enum>
              <header>Informing
				beneficiaries</header>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall take steps to inform beneficiaries about the availability of a Medicare
				operated drug plan or plans including providing information in the annual
				handbook distributed to all beneficiaries and adding information to the
				official public Medicare Web site related to prescription drug coverage
				available through this part.</text>
						</subsection>
            <subsection id="H8B8F5E67084D47F19743979DFCF89AFA">
              <enum>(g)</enum>
              <header>Application of
				all other requirements for prescription drug plans</header>
              <text>Except as
				specifically provided in this section, any Medicare operated drug plan shall
				meet the same requirements as apply to any other prescription drug plan,
				including the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D–4/ss:b/p:1">section 1860D–4(b)(1)</cato:entity-ref> relating to assuring
				pharmacy
				access).</text>
						</subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="HEBD4A6E474E8460FB85F49F75C5E1E58">
        <enum>(b)</enum>
        <header>Conforming
			 amendments</header>
				<paragraph id="H307D5E4F23C44E6FAA261C842D010F8E">
          <enum>(1)</enum>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Social Security Act/s:1860D–3/ss:a">Section 1860D–3(a)
			 of the <act-name parsable-cite="SSA">Social Security Act</act-name>
              </cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/1395w–103/a">42 U.S.C.
			 1395w–103(a)</cato:entity-ref>)</cato:entity> is amended by adding at the end the following new
			 paragraph:</text>
					<quoted-block act-name="Social Security Act" id="HC4DC782AA4C54F1293A1AEED72434261">
						<paragraph id="H52FB1342792F43DF8CA88FBA0FC58209">
              <enum>(4)</enum>
              <header>Availability of
				the medicare operated prescription drug plan</header>
              <text>A Medicare operated
				prescription drug plan (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D–11A/ss:c">section 1860D–11A(c)</cato:entity-ref>) shall be offered
				nationally in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D–11A">section
				1860D–11A</cato:entity-ref>.</text>
						</paragraph>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
        <paragraph display-inline="no-display-inline" id="H7814F1BFBDBC4B1681EE683C305CA323">
          <enum>(2)</enum>
          <subparagraph commented="no" display-inline="yes-display-inline" id="H982EDE6AB8154E219C88BD472FAF302A">
            <enum>(A)</enum>
            <text>
              <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                <cato:entity-ref entity-type="act" value="Social Security Act/s:1860D–3">Section 1860D–3 of the
			 Social Security Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/1395w–103">42 U.S.C. 1395w–103</cato:entity-ref>)</cato:entity> is amended by adding at the end the
			 following new subsection:</text>
						<quoted-block id="H8D74A16A15A04567AB86DA4BF6A9920E" style="OLC">
							<subsection id="H9DF5C268352B45E78988D61C5E3E11D8">
                <enum>(c)</enum>
                <header>Provisions only
				applicable in 2006 through 2013</header>
                <text>The provisions of this section
				shall only apply with respect to 2006 through
				2013.</text>
							</subsection>
              <after-quoted-block>.</after-quoted-block>
            </quoted-block>
					</subparagraph>
          <subparagraph id="HB6F9287B81174B10901B64188AF61273" indent="up1">
            <enum>(B)</enum>
            <text>
              <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                <cato:entity-ref entity-type="act" value="Social Security Act/s:1860D–11/ss:g">Section 1860D–11(g) of such Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/1395w–111/g">42
			 U.S.C. 1395w–111(g)</cato:entity-ref>)</cato:entity> is amended by adding at the end the following new
			 paragraph:</text>
						<quoted-block id="H9A7F457888EC46E2B97582CE544CBD56" style="OLC">
							<paragraph id="H31AC20D299484B16BB6A8ED4DA0D2178">
                <enum>(8)</enum>
                <header>No authority for
				fallback plans after 2013</header>
                <text>A fallback prescription drug plan shall
				not be available after December 31,
				2013.</text>
							</paragraph>
              <after-quoted-block>.</after-quoted-block>
            </quoted-block>
					</subparagraph>
        </paragraph>
        <paragraph id="H012F332316194CF980B66A1C6E6FB6A9">
          <enum>(3)</enum>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Social Security Act/s:1860D–13/ss:c/p:3">Section
			 1860D–13(c)(3) of the Social Security Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/1395w–113/c/3">42 U.S.C. 1395w–113(c)(3)</cato:entity-ref>)</cato:entity> is
			 amended—</text>
					<subparagraph id="HDAC70F910EE747FEAC253D5D8B0FE541">
            <enum>(A)</enum>
            <text>in the heading, by
			 inserting <quote>
                <header-in-text level="paragraph" style="OLC">and Medicare
			 operated prescription drug plans</header-in-text>
              </quote> after
			 <quote>
                <header-in-text level="paragraph" style="OLC">Fallback
			 plans</header-in-text>
              </quote>; and</text>
					</subparagraph>
          <subparagraph id="H4A7F8FF858D44B89BA4C7AB09A4A0D7C">
            <enum>(B)</enum>
            <text display-inline="yes-display-inline">by inserting <quote>or a Medicare operated
			 prescription drug plan</quote> after <quote>a fallback prescription drug
			 plan</quote>.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="HC4E31891264B40AF8A73BB81CEEFDB68">
          <enum>(4)</enum>
          <text display-inline="yes-display-inline">
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Social Security Act/s:1860D–16/ss:b/p:1">Section 1860D–16(b)(1) of the Social
			 Security Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc">42 U.S.C.1395w–116(b)(1)</cato:entity-ref>)</cato:entity> is amended—</text>
					<subparagraph id="H55027CA8E63A4BCFBB5471290E458AC3">
            <enum>(A)</enum>
            <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D–16/ss:b/p:1/sp:C">subparagraph
			 (C)</cato:entity-ref>, by striking <quote>and</quote> after the semicolon at the end;</text>
					</subparagraph>
          <subparagraph id="H4F3965E9CF2C43C681705BA58DF35662">
            <enum>(B)</enum>
            <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D–16/ss:b/p:1/sp:D">subparagraph
			 (D)</cato:entity-ref>, by striking the period at the end and inserting <quote>; and</quote>;
			 and</text>
					</subparagraph>
          <subparagraph id="H63023BBC588D4E6F81ECC61B339DB3F5">
            <enum>(C)</enum>
            <text>by adding at the
			 end the following new subparagraph:</text>
						<quoted-block id="H41A9D75961FB4D70994A874A8A4A513F">
							<subparagraph id="HAAB9BB2D7E1B47C2AACC34FA9746B2D7">
                <enum>(E)</enum>
                <text>payments for
				expenses incurred with respect to the operation of Medicare operated
				prescription drug plans under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D–11A">section
				1860D–11A</cato:entity-ref>.</text>
							</subparagraph>
              <after-quoted-block>.</after-quoted-block>
            </quoted-block>
					</subparagraph>
        </paragraph>
        <paragraph id="HE00E39337E58467A97F56617C4106DD8">
          <enum>(5)</enum>
          <text display-inline="yes-display-inline">
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Social Security Act/s:1860D–41/ss:a">Section 1860D–41(a) of the Social Security
			 Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/1395w–151/a">42 U.S.C. 1395w–151(a)</cato:entity-ref>)</cato:entity> is amended by adding at the end the following new
			 paragraph:</text>
					<quoted-block id="HC129E958BEB24B778648748091AF1309">
						<paragraph id="HBD9BC53702D34848AAA90450E647C0FE">
              <enum>(19)</enum>
              <header>Medicare
				operated prescription drug plan</header>
              <text>The term <term>Medicare operated
				prescription drug plan</term> has the meaning given such term in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D–11A/ss:c">section
				1860D–11A(c)</cato:entity-ref>.</text>
						</paragraph>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
      </subsection>
    </section>
    <section id="HAE9B65482C234375865B37E3074DA8D2">
      <enum>3.</enum>
      <header>Improved appeals
			 process under the Medicare operated prescription drug plan</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Social Security Act/s:1860D–4/ss:h">Section 1860D–4(h) of the Social Security
			 Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/1305w–104/h">42 U.S.C. 1305w–104(h)</cato:entity-ref>)</cato:entity> is amended by adding at the end the following new
			 paragraph:</text>
			<quoted-block display-inline="no-display-inline" id="H34A64632A019475EB09791411B1021DA" style="OLC">
				<paragraph id="HFA6E76987EE4464E8B9AE70C3B2A484A">
          <enum>(4)</enum>
          <header>Appeals process
				for Medicare operated prescription drug plan</header>
					<subparagraph id="H82BC9EBCFD9449AE9756F70C9F672DD9">
            <enum>(A)</enum>
            <header>In
				general</header>
            <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				develop a well-defined process for appeals for denials of benefits under this
				part under the Medicare operated prescription drug plan. Such process shall be
				efficient, impose minimal administrative burdens, and ensure the timely
				procurement of non-formulary drugs or exemption from formulary incentives when
				medically necessary. Medical necessity shall be based on professional medical
				judgment, the medical condition of the beneficiary, and other medical evidence.
				Such appeals process shall include—</text>
						<clause id="HA5A0BCBF8A8746BB89926B7C8DC52182">
              <enum>(i)</enum>
              <text>an
				initial review and determination made by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>; and</text>
						</clause>
            <clause id="H1A4482F7CA1A4FE99251C790BD1FE9DC">
              <enum>(ii)</enum>
              <text>for appeals
				denied during the initial review and determination, the option of an external
				review and determination by an independent entity selected by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
						</clause>
          </subparagraph>
          <subparagraph id="H22CF58D5CAAF486A8BA2AE8F81DC7C3E">
            <enum>(B)</enum>
            <header>Consultation in
				development of process</header>
            <text>In developing the appeals process under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D–4/ss:h/p:4/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall consult with consumer and patient groups,
				as well as other key stakeholders to ensure the goals described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1860D–4/ss:h/p:4/sp:A" proposed="true">subparagraph
				(A)</cato:entity-ref> are
				achieved.</text>
					</subparagraph>
        </paragraph>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
  </legis-body>
</bill>
</doc>